NASDAQ:IDIX Idenix Pharmaceuticals (IDIX) Stock Price, News & Analysis → Warren Buffett's 'mystery stock' (From Stansberry Research) (Ad) Free IDIX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Idenix Pharmaceuticals alerts: Email Address Ad InvestorPlaceRead this before you buy AI stocksBREAKING: New "Formula" Could Lead to Huge AI Payouts When you click here and see what Elon Musk's new invention does… Investors — including multiple billionaires — are now tapping into a unique AI secret to pocket huge, consistent payouts. Starting today, you could siphon a new stream of income from this $3 billion pool of cash. About Idenix Pharmaceuticals Stock (NASDAQ:IDIX)Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719. The Company, as of December 31, 2012, was developing nucleotide polymerase inhibitors and NS 5A inhibitors to inhibits HCV replication, which include nucleoside/nucleotide polymerase inhibitors and NS5A Inhibitors. On January 25, 2013, the Company entered into a non-exclusive collaboration agreement with Janssen Pharmaceuticals, Inc for the clinical evaluation of all oral DAA HCV combination therapies.Read More Ad InvestorPlaceRead this before you buy AI stocksBREAKING: New "Formula" Could Lead to Huge AI Payouts When you click here and see what Elon Musk's new invention does… Investors — including multiple billionaires — are now tapping into a unique AI secret to pocket huge, consistent payouts. Starting today, you could siphon a new stream of income from this $3 billion pool of cash. IDIX Stock News HeadlinesMay 17, 2024 | investing.comDow Jones Pharmaceuticals & Biotechnology (DJUSPN)May 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT), Syndax Pharmaceuticals (SNDX) and Tarsus Pharmaceuticals (TARS)April 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and Madrigal Pharmaceuticals (MDGL)April 5, 2024 | wsj.comiShares U.S. Pharmaceuticals ETFMarch 20, 2024 | markets.businessinsider.comPositive Outlook for Citius Pharmaceuticals with Lymphir’s FDA Resubmission and Market PotentialMarch 18, 2024 | markets.businessinsider.comImprimis Pharmaceuticals earnings: here's what Wall Street expectsJanuary 22, 2024 | wsj.comNYSE Arca Pharmaceutical IndexJanuary 4, 2024 | markets.businessinsider.comRigel Pharma Collaborates With CONNECT To Conduct Phase 2 Trial Of Olutasidenib In GliomaNovember 27, 2023 | benzinga.comWhy Biodexa Pharmaceuticals Stock (BDRX) Is SkyrocketingOctober 11, 2023 | markets.businessinsider.comHold Rating on Inovio Pharmaceuticals: Potential Expedited Approval and Commercialization of INO-3107 for Recurrent Respiratory PapillomatosisSeptember 26, 2023 | benzinga.comNexus Pharmaceuticals Receives FDA Approval for Fluorescein Injection, USPSeptember 26, 2023 | msn.comWhy Intercept Pharmaceuticals Stock Is Skyrocketing TodaySeptember 11, 2023 | investing.comKOSDAQ Pharmaceuticals Technical AnalysisAugust 11, 2023 | msn.comChina drugmakers axe IPO plans as they face scrutiny in anti-graft driveJuly 20, 2023 | morningstar.comInDex Pharmaceuticals Holding ABJuly 16, 2023 | investing.comLegal & General Global Health & Pharmaceuticals Index Trust R Class Accumulation (0P00000C79)June 29, 2023 | markets.businessinsider.comEndo International Says Health Canada Approves XCOPRI To Treat EpilepsyJune 21, 2023 | benzinga.comBoard Member at Impel Pharmaceuticals Acquires Company Stock Options Worth 13,222 SharesJune 12, 2023 | cnn.comFirst-of-its-kind erectile dysfunction gel gets FDA’s OK for over-the-counter marketing, company saysJune 3, 2023 | reuters.comDrugmaker Mallinckrodt may file for bankruptcy again -WSJMay 28, 2023 | wsj.comS&P 500 Pharmaceuticals Biotechnology & Life Sciences Industry Group IndexMay 17, 2023 | thestreet.comMerck Adds HCV Candidates with Idenix BuyApril 7, 2023 | investing.comInDex Pharmaceuticals Holding AB (INDEX)April 6, 2023 | investing.comTOPIX Pharmaceutical Technical AnalysisMarch 22, 2023 | markets.businessinsider.comHere's what Wall Street expects from Imprimis Pharmaceuticals's earningsSee More Headlines Receive IDIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Idenix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:IDIX CUSIP45166R20 CIK1093649 Webwww.idenix.com Phone+1-617-9959800FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report IDIX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Idenix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Idenix Pharmaceuticals investors own include Ariad Pharmaceuticals (ARIA), Arena Pharmaceuticals (ARNA), Dendreon (DNDNQ), Gilead Sciences (GILD), AbbVie (ABBV), Achillion Pharmaceuticals (ACHN), AEGR (AEGR), Aeterna Zentaris (AEZS), Amarin (AMRN) and BlackBerry (BB). This page (NASDAQ:IDIX) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap Profits4 Cryptos BETTER than BitcoinTrue Market Insiders[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaBill Clinton Backing Biden Replacement???The Freeport SocietyTop 5 Tech Stocks to Buy for 2024Daily Market AlertsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Idenix Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.